What Is the FDA Guidance for Ozempic?

What Exactly Has the FDA Approved Ozempic For?

The FDA has granted Ozempic two distinct on-label indications. First: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Second: to reduce the risk of major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in adults with type 2 diabetes and established cardiovascular disease. Both indications appear in the current Ozempic prescribing information maintained on the FDA's Drugs@FDA database. [1]

Ozempic is not approved for chronic weight management. That indication belongs to Wegovy (semaglutide 2.4 mg), which received its own separate FDA approval in June 2021 under a different NDA (NDA 215256). [2] Confusing the two products is a common error in consumer media.

The 2017 Initial Approval

The FDA approved Ozempic on December 5, 2017, based primarily on the SUSTAIN clinical trial program. [1] The initial approved doses were 0.5 mg and 1 mg weekly. Glycemic efficacy data from SUSTAIN-1 through SUSTAIN-5 supported the label claim for blood-sugar control.

The 2020 Cardiovascular Indication Expansion

In 2020, the FDA added the cardiovascular risk-reduction indication following results from SUSTAIN-6 (N=3,297). That trial showed a statistically significant 26% relative risk reduction in three-point MACE (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority, P=0.02 for superiority) vs. Placebo over 104 weeks. [3] The NNT for MACE prevention was approximately 45 over two years.

The 2 mg Dose Added in 2022

In March 2022, the FDA approved a 2 mg once-weekly dose of Ozempic as an additional maintenance option for adults with type 2 diabetes. [4] The SUSTAIN FORTE trial (N=961) showed HbA1c reductions of 2.0 percentage points with 2 mg vs. 1.8 percentage points with 1 mg at 40 weeks. [5]

What Does the FDA-Approved Dosing Schedule Look Like?

The Ozempic label specifies a structured four-phase escalation designed to reduce gastrointestinal side effects. Starting too high too fast is the most common reason patients discontinue early.

Starting Dose

Prescribers initiate Ozempic at 0.25 mg subcutaneously once weekly for four weeks. This dose is for tolerability only and carries no meaningful glycemic effect on its own. [1]

Maintenance Dose Options

After four weeks, the dose increases to 0.5 mg once weekly. If additional glycemic control is needed after at least four weeks at 0.5 mg, the prescriber may escalate to 1 mg once weekly. If glycemic targets remain unmet after at least four weeks at 1 mg, further escalation to 2 mg once weekly is permitted. [1]

The injection is given subcutaneously in the abdomen, thigh, or upper arm. Injection site and time of day may change week to week without adjusting for meals. [1]

Missed Dose Instructions

Per the FDA label, a missed dose may be administered within five days of the scheduled day. If more than five days have elapsed, skip that dose and resume the regular weekly schedule. Never double-dose. [1]

What Are the FDA's Key Safety Warnings for Ozempic?

Boxed Warning: Thyroid C-Cell Tumors

The Ozempic label carries a black-box warning regarding thyroid C-cell tumors. In rodent studies, semaglutide caused dose-dependent thyroid C-cell tumors. It is unknown whether this finding translates to humans, but the FDA requires the warning because the relevance cannot be excluded. [1]

Ozempic is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]

Prescribers should counsel patients to report neck masses, dysphagia, dyspnea, or persistent hoarseness promptly. The FDA updated the MTC postmarket surveillance requirements in 2021. [6]

Pancreatitis

The label warns of acute pancreatitis, including fatal and non-fatal cases, reported post-approval. Ozempic should be discontinued if pancreatitis is suspected and not restarted if confirmed. [1] The American Diabetes Association's 2024 Standards of Care note that the absolute risk increase for pancreatitis with GLP-1 receptor agonists remains small in randomized trial data. [7]

Diabetic Retinopathy Complications

SUSTAIN-6 detected a higher rate of diabetic retinopathy complications in the semaglutide group (3.0%) vs. Placebo (1.8%; HR 1.76; 95% CI 1.11 to 2.78). [3] The label requires monitoring patients with a history of diabetic retinopathy. Rapid HbA1c reduction, not a direct drug toxicity, is the leading proposed mechanism. [8]

Hypoglycemia

Ozempic itself does not commonly cause hypoglycemia in monotherapy. The risk rises substantially when it is combined with a sulfonylurea or insulin. Dose reduction of the concomitant agent may be necessary. In SUSTAIN-1, severe or blood glucose-confirmed hypoglycemia occurred in 0% of semaglutide 0.5 mg subjects vs. 0% with placebo over 30 weeks when used without secretagogues. [9]

Acute Kidney Injury

Post-marketing reports describe acute kidney injury, sometimes requiring dialysis, mostly in patients who experienced nausea, vomiting, or diarrhea-related dehydration. Volume status should be monitored, particularly in patients on diuretics or ACE inhibitors. [1]

Heart Rate Increase

The label documents a mean increase in resting heart rate of 2 to 3 beats per minute. Monitoring is recommended in patients with pre-existing tachycardia or history of arrhythmia. [1]

How Does Ozempic Differ From Wegovy According to the FDA?

Both products contain semaglutide. The FDA treats them as pharmacologically related but legally distinct products under separate NDAs with separate labels, separate approved indications, and different pen delivery systems.

| Feature | Ozempic | Wegovy | |---|---|---| | NDA | 209637 | 215256 | | Approved indication | T2D glycemic control; CV risk reduction | Chronic weight management (BMI ≥30, or ≥27 with comorbidity) | | Maximum approved dose | 2 mg/week | 2.4 mg/week | | FDA approval year | 2017 | 2021 | | Age indication | Adults | Adults and adolescents ≥12 (added 2023) |

Wegovy's weight-management approval rested primarily on the STEP-1 trial (N=1,961), where semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks vs. 2.4% with placebo (P<0.001). [10] Ozempic's label does not mention weight loss as a target outcome.

What Is Off-Label Use, and Is Prescribing Ozempic for Weight Loss Legal?

Off-label prescribing is legal and common in the United States. The FDA regulates drug approval, not physician prescribing practice. Once a drug is approved for any indication, a licensed clinician may prescribe it for other conditions based on clinical judgment and available evidence. [11]

Physicians who prescribe Ozempic for weight management in patients without type 2 diabetes are practicing legal off-label medicine. The FDA does not prohibit this. What the FDA does prohibit is marketing Ozempic for unapproved uses; that obligation falls on Novo Nordisk, not the prescribing physician. [11]

The HealthRX clinical team uses the following decision framework when evaluating a patient for semaglutide therapy:

1. Does the patient have type 2 diabetes? If yes, Ozempic (any approved dose) is on-label and typically the first-line GLP-1 choice per ADA 2024 Standards. [7]
2. Does the patient have T2D plus ASCVD? If yes, the cardiovascular indication further supports Ozempic selection, and the SUSTAIN-6 data directly apply. [3]
3. Does the patient have obesity (BMI ≥30) without T2D? Wegovy 2.4 mg is the on-label option. Ozempic is off-label in this context but clinically defensible given the shared molecule and STEP trial program data.
4. Does the patient have overweight (BMI 27 to 29.9) with a weight-related comorbidity? Wegovy covers this; Ozempic is off-label.
5. Are there contraindications? History of MTC, MEN 2, prior hypersensitivity to semaglutide, or pregnancy disqualifies both products.

How Do Telehealth Programs Like Calibrate Use Ozempic?

Calibrate is a metabolic health platform that pairs GLP-1 medications with a structured lifestyle-coaching curriculum. The program's physicians may prescribe Ozempic (semaglutide) for eligible members, particularly those with type 2 diabetes or when Wegovy is unavailable or cost-prohibitive.

Calibrate's Medical Eligibility Criteria

Calibrate requires a licensed physician or nurse practitioner to evaluate each member. Prescribing follows FDA safety guidance: the program screens for thyroid cancer history, pancreatitis history, MEN 2, and pregnancy. Prior authorization from the member's insurer is typically required because most payers cover Ozempic only for documented type 2 diabetes. [12]

Insurance Coverage Differences

This is where the Ozempic-vs.-Wegovy distinction matters practically. Medicare Part D covers Ozempic for T2D under most formularies but does not cover Wegovy for weight loss under traditional Medicare (the Inflation Reduction Act excluded weight-loss drugs from mandatory coverage through at least 2025). [13] Commercial plans vary widely. Calibrate's patient advocates typically assist with prior authorization documentation.

Compounded Semaglutide and FDA Warnings

During the 2022 to 2024 Ozempic shortage, compounding pharmacies produced semaglutide formulations that some telehealth platforms dispensed. The FDA issued multiple safety communications warning that compounded semaglutide is not FDA-approved and that compounded products may contain different salts (semaglutide sodium or acetate rather than the base form used in Ozempic/Wegovy) with unknown clinical equivalence. [14] As of early 2025, FDA declared the shortage resolved for Ozempic and Wegovy, which affects the legal basis for compounding under 503A/503B rules. [14]

What Does Current Clinical Evidence Say About Ozempic's Effectiveness?

Glycemic Control Data

Across the SUSTAIN program, semaglutide 1 mg reduced HbA1c by 1.5 to 1.8 percentage points vs. 0.4 to 1.1 percentage points with comparators including sitagliptin, exenatide ER, and insulin glargine. [9] The ADA 2024 Standards of Care list GLP-1 receptor agonists as preferred agents after metformin for adults with T2D and high cardiovascular risk, obesity, or risk of hypoglycemia. [7]

Cardiovascular Outcomes

SUSTAIN-6 was a 104-week, randomized, double-blind, placebo-controlled trial (N=3,297) specifically designed to assess cardiovascular safety. Semaglutide met both noninferiority and superiority thresholds. CV death occurred in 2.7% (semaglutide) vs. 2.8% (placebo); nonfatal MI in 2.9% vs. 3.9%; nonfatal stroke in 1.6% vs. 2.7%. [3] The American Heart Association's 2023 guidance on GLP-1 therapy in cardiometabolic disease cites SUSTAIN-6 as establishing cardiovascular benefit. [15]

SELECT Trial: Ozempic in People Without Diabetes

The SELECT trial (N=17,604) studied semaglutide 2.4 mg (the Wegovy dose) in adults with obesity and established CVD but without diabetes. It showed a 20% relative risk reduction in MACE (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). [16] Although SELECT used the Wegovy dose rather than Ozempic doses, the data inform clinical thinking about the class broadly. The FDA approved a cardiovascular risk-reduction label expansion for Wegovy based on SELECT in March 2024. [16]

Weight Loss as a Secondary Outcome

In SUSTAIN-1 through SUSTAIN-8, semaglutide 1 mg produced weight reductions of 4.5 to 6.5 kg vs. Comparators. This is meaningfully less than the 15 kg seen in STEP-1 with the 2.4 mg Wegovy dose, which reflects the dose-response relationship of semaglutide. [10]

What Should Patients Know Before Starting Ozempic?

Common Side Effects

Gastrointestinal effects dominate the early weeks. In SUSTAIN-1, nausea occurred in 20.3% of semaglutide 0.5 mg subjects vs. 6.1% with placebo. [9] Vomiting (7.3% vs. 2.0%) and diarrhea (9.0% vs. 4.1%) also ran higher with semaglutide. Most GI events are mild to moderate and peak during the first 8 to 12 weeks of dose escalation.

Injection Technique

The Ozempic pen requires subcutaneous injection. Patients rotate sites to prevent lipohypertrophy. Needles are not reusable. Pens in use may be kept at room temperature (below 30°C / 86°F) for up to 56 days; unused pens should remain refrigerated at 2 to 8°C. [1]

Drug Interactions

Ozempic slows gastric emptying, which may reduce peak absorption of oral medications taken concomitantly. This effect is most clinically relevant for time-sensitive oral drugs such as levothyroxine or oral contraceptives. The FDA label advises caution and potentially taking time-sensitive medications at least 1 hour before the Ozempic injection on dosing day. [1]

Pregnancy and Lactation

Ozempic is contraindicated in pregnancy. Animal studies show fetal harm at clinically relevant doses. Women of childbearing potential should use contraception. Because semaglutide has a half-life of approximately one week and takes about five weeks to clear, the FDA label advises discontinuing Ozempic at least two months before a planned pregnancy. [1] No human lactation data exist; clinicians should weigh risks carefully. [17]

How Does the FDA Monitor Ozempic Post-Approval?

MedWatch and FAERS

The FDA collects post-approval safety data through MedWatch reports and the FDA Adverse Event Reporting System (FAERS). Clinically significant reports in the FAERS database for semaglutide products include cases of gastroparesis, intestinal obstruction, suicidal ideation (under active evaluation), and pulmonary aspiration during anesthesia. [18]

2023 FDA Investigation: Suicidal Ideation

In 2023, the FDA announced it was evaluating reports of suicidal ideation with GLP-1 receptor agonists, including semaglutide, liraglutide, and others. A 2024 analysis of insurance claims data (N=240,618) published in Nature Medicine found no statistically significant association between semaglutide and suicidal ideation; the risk was, if anything, lower in semaglutide users. [19] The FDA has not required a label change as of mid-2025, but monitoring continues.

Anesthesia and Aspiration Risk

In June 2023, the American Society of Anesthesiologists issued guidance recommending that patients on GLP-1 receptor agonists consider withholding the weekly dose for at least one week prior to elective procedures requiring general anesthesia, due to delayed gastric emptying and aspiration risk. [20] The FDA has not issued a formal label revision on this point but has updated patient communications. [18]